Glaucoma – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Glaucoma – Pipeline Review, H2 2019’, provides an overview of the Glaucoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Glaucoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Glaucoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.”

Scope


– The report provides a snapshot of the global therapeutic landscape of Glaucoma

– The report reviews pipeline therapeutics for Glaucoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Glaucoma therapeutics and enlists all their major and minor projects

– The report assesses Glaucoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Glaucoma”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Glaucoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Glaucoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

“AC Immune SA

Acorn Biomedical Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Allergan Plc

Amarantus Bioscience Holdings Inc

Amgen Inc

Annexon Inc

Ascentage Pharma Group International

Asha Vision LLC

Betaliq Inc

Bial – Portela & Ca SA

BioAxone BioSciences Inc

Califia Bio Inc

Calpain Therapeutics Pty Ltd

Cellix Bio Pvt Ltd

Certa Therapeutics Pty Ltd

Chong Kun Dang Pharmaceutical Corp

D. Western Therapeutics Institute Inc

Deha Pharmaceutical LLC

Dhp Korea Ltd

Disarm Therapeutics Inc

Dompe Farmaceutici SpA

Emerald Bioscience Inc

Envisia Therapeutics Inc

Evotec SE

Eyenovia Inc

EyePoint Pharmaceuticals Inc

Eyevensys SAS

Fortress Biotech Inc

Future Medicine Co Ltd

Galimedix Therapeutics Ltd

Gene Signal International SA

Glaukos Corp

Graybug Vision Inc

Guangzhou Cellprotek Pharmaceutical Co Ltd

Guangzhou Magpie Pharmaceutical Co Ltd

Handok Inc

HitGen LTD

ID Pharma Co Ltd

InMed Pharmaceuticals Inc

Inspyr Therapeutics Inc

Isarna Therapeutics GmbH

Kodiak Sciences Inc

Kukje Pharmaceutical Industry Co Ltd

Kyoto Drug Discovery & Development Co Ltd

Laboratorios SALVAT SA

Laboratorios Sophia SA de CV

LayerBio Inc

Lee’s Pharmaceutical Holdings Ltd

Matrix Biomed Inc

MimeTech Srl

MyX Therapeutics Inc

Nanoscope Therapeutics Inc

NeuBase Therapeutics Inc

NeurAegis Inc

Neurim Pharmaceuticals Ltd

Neurizon Pharma GBR

Neuroptika Inc

NicOx SA

NoNO Inc

Novaliq GmbH

Novartis AG

Noveome Biotherapeutics Inc

Novoron Bioscience Inc

Ocular Therapeutix Inc

Oculo Therapy LLC

Ocuphire Pharma Inc

Oncolys BioPharma Inc

ONL Therapeutics Inc

Palo BioFarma SL

pH Pharma Co Ltd

Pivot Pharmaceuticals Inc

Profarma

Q BioMed Inc

Qlaris Bio Inc

Quark Pharmaceuticals Inc

Quethera Ltd

Qurgen Inc

Radikal Therapeutics Inc

Regeneron Pharmaceuticals Inc

ReNetX Bio

Santen Pharmaceutical Co Ltd

Senju Pharmaceutical Co Ltd

Sun Pharma Advanced Research Company Ltd

Sustained Nano Systems LLC

Suzhou Ribo Life Sciences Co Ltd

Sylentis SAU

Taejoon Pharm Co Ltd

Takeda Pharmaceutical Co Ltd

Teraclon IDF SL

TikoMed AB

Toa Eiyo Ltd

ViSci Ltd

Whitecap Biosciences LLC”

Table of Contents

Table of Contents

Table of Contents 2

Introduction 6

Glaucoma Overview 7

Glaucoma Therapeutics Development 8

Glaucoma Therapeutics Assessment 23

Glaucoma Companies Involved in Therapeutics Development 35

Glaucoma Drug Profiles 63

Glaucoma Dormant Projects 277

Glaucoma Discontinued Products 283

Glaucoma Product Development Milestones 285

Appendix 294

List of Tables

“List of Tables

Table 1: Number of Products under Development for Glaucoma, H2 2019

Table 2: Number of Products under Development by Companies, H2 2019

Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 5: Number of Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 6: Number of Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 7: Number of Products under Development by Universities/Institutes, H2 2019

Table 8: Products under Development by Companies, H2 2019

Table 9: Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Table 10: Products under Development by Companies, H2 2019 (Contd..2), H2 2019

Table 11: Products under Development by Companies, H2 2019 (Contd..3), H2 2019

Table 12: Products under Development by Companies, H2 2019 (Contd..4), H2 2019

Table 13: Products under Development by Companies, H2 2019 (Contd..5), H2 2019

Table 14: Products under Development by Companies, H2 2019 (Contd..6), H2 2019

Table 15: Products under Development by Companies, H2 2019 (Contd..7), H2 2019

Table 16: Products under Development by Universities/Institutes, H2 2019

Table 17: Number of Products by Stage and Target, H2 2019

Table 18: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019

Table 19: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019

Table 20: Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019

Table 21: Number of Products by Stage and Mechanism of Action, H2 2019

Table 22: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019

Table 23: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019

Table 24: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019

Table 25: Number of Products by Stage and Route of Administration, H2 2019

Table 26: Number of Products by Stage and Molecule Type, H2 2019

Table 27: Glaucoma – Pipeline by AC Immune SA, H2 2019

Table 28: Glaucoma – Pipeline by Acorn Biomedical Inc, H2 2019

Table 29: Glaucoma – Pipeline by Aerie Pharmaceuticals Inc, H2 2019

Table 30: Glaucoma – Pipeline by Aerpio Pharmaceuticals Inc, H2 2019

Table 31: Glaucoma – Pipeline by Allergan Plc, H2 2019

Table 32: Glaucoma – Pipeline by Amarantus Bioscience Holdings Inc, H2 2019

Table 33: Glaucoma – Pipeline by Amgen Inc, H2 2019

Table 34: Glaucoma – Pipeline by Annexon Inc, H2 2019

Table 35: Glaucoma – Pipeline by Ascentage Pharma Group International, H2 2019

Table 36: Glaucoma – Pipeline by Asha Vision LLC, H2 2019

Table 37: Glaucoma – Pipeline by Betaliq Inc, H2 2019

Table 38: Glaucoma – Pipeline by Bial – Portela & Ca SA, H2 2019

Table 39: Glaucoma – Pipeline by BioAxone BioSciences Inc, H2 2019

Table 40: Glaucoma – Pipeline by Califia Bio Inc, H2 2019

Table 41: Glaucoma – Pipeline by Calpain Therapeutics Pty Ltd, H2 2019

Table 42: Glaucoma – Pipeline by Cellix Bio Pvt Ltd, H2 2019

Table 43: Glaucoma – Pipeline by Certa Therapeutics Pty Ltd, H2 2019

Table 44: Glaucoma – Pipeline by Chong Kun Dang Pharmaceutical Corp, H2 2019

Table 45: Glaucoma – Pipeline by D. Western Therapeutics Institute Inc, H2 2019

Table 46: Glaucoma – Pipeline by Deha Pharmaceutical LLC, H2 2019

Table 47: Glaucoma – Pipeline by Dhp Korea Ltd, H2 2019

Table 48: Glaucoma – Pipeline by Disarm Therapeutics Inc, H2 2019

Table 49: Glaucoma – Pipeline by Dompe Farmaceutici SpA, H2 2019

Table 50: Glaucoma – Pipeline by Emerald Bioscience Inc, H2 2019

Table 51: Glaucoma – Pipeline by Envisia Therapeutics Inc, H2 2019

Table 52: Glaucoma – Pipeline by Evotec SE, H2 2019

Table 53: Glaucoma – Pipeline by Eyenovia Inc, H2 2019

Table 54: Glaucoma – Pipeline by EyePoint Pharmaceuticals Inc, H2 2019

Table 55: Glaucoma – Pipeline by Eyevensys SAS, H2 2019

Table 56: Glaucoma – Pipeline by Fortress Biotech Inc, H2 2019

Table 57: Glaucoma – Pipeline by Future Medicine Co Ltd, H2 2019

Table 58: Glaucoma – Pipeline by Galimedix Therapeutics Ltd, H2 2019

Table 59: Glaucoma – Pipeline by Gene Signal International SA, H2 2019

Table 60: Glaucoma – Pipeline by Glaukos Corp, H2 2019”

List of Figures

“List of Figures

Figure 1: Number of Products under Development for Glaucoma, H2 2019

Figure 2: Number of Products under Development by Companies, H2 2019

Figure 3: Number of Products under Development by Universities/Institutes, H2 2019

Figure 4: Number of Products by Top 10 Targets, H2 2019

Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019

Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019

Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019

Figure 8: Number of Products by Top 10 Routes of Administration, H2 2019

Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H2 2019

Figure 10: Number of Products by Top 10 Molecule Types, H2 2019

Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports